What Is Mustang Bio, Inc. (MBIO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Mustang Bio, Inc.'s intrinsic value is estimated at a composite fair value of $1.74. At a current market price of $0.63, 6 of 6 active valuation models identify upside potential, projecting an average implied return of +175.8%. Notably, CUCE sees the most upside at +414.8% (fair value: $3.25), while PWERM is the most conservative at +6.2% ($0.67). The spread between these extremes — +408.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MBIO?
6 of 13 models are currently active for MBIO. All 6 active models suggest the stock trades below fair value. The Bayesian DCF estimates MBIO's intrinsic value at $1.23, implying +94.0% upside from the current price. See which stocks rank higher →
How Does MBIO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, MBIO ranks #382 by Quality of Company score. CirclFi's QOC score of 3.3/10 evaluates 32 fundamental signals. A score of 3.3 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Mustang Bio, Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating MBIO should weigh these sector-specific dynamics alongside our model-derived fair values.
Is MBIO a Value Trap?
CirclFi's Value Trap algorithm assigns MBIO a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
6 of 13 models are active for Mustang Bio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Mustang Bio, Inc.'s fundamental quality profile registers 3.3/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +408.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MBIO's 6 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad